title: Role of hematopoietic stem cell transplantation in multiple myeloma.
abstract: High-dose therapy followed by autologous stem cell transplantation (ASCT) has been the standard frontline consolidative therapy for patients with newly diagnosed multiple myeloma (MM) for > 2 decades. This approach has resulted in higher complete response (CR) rates and increased event-free survival and overall survival (OS) compared with conventional chemotherapy. The emergence of novel agent-based therapy combined with ASCT has revolutionized MM therapy by improving the CR rates and OS, raising questions concerning the role of hematopoietic stem cell transplantation in this setting.
authors.affiliation: Department of Hematology Oncology, University of Chicago Medical Center, Chicago, IL. Electronic address: igarcia@medicine.bsd.uchicago.edu.
authors.forename: Ima N
authors.initials: IN
authors.lastname: Garcia
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome
keywords: Conventional chemotherapy; High Dose Therapy; Maintenance therapy; Novel agents; Transplant Eligible